Jiangxi Serum Pharma Industries Co., Ltd. stands as a beacon of reliability in the global pharmaceutical landscape. For nearly a decade, we have pioneered the export of high-potency biological products, including Hepatitis B Human Immunoglobulin, vaccines, and essential raw materials. Our mission is to bridge the gap between advanced Chinese manufacturing and global healthcare needs.
Comprehensive Insights into Passive Immunization, Manufacturing Standards, and Global Procurement Strategies
Hepatitis B Human Immunoglobulin (HBIG) is a sterile solution of ready-to-use antibodies (immunoglobulins) derived from human plasma containing high titers of anti-HBs. Unlike vaccines which provide active immunity over time, HBIG provides immediate, passive immunity. This is vital in critical windows such as:
China has emerged as a global hub for plasma-derived medicinal products (PDMPs). Leveraging Jiangxi Serum Pharma’s network, we provide a distinct competitive edge:
Stringent Plasma Screening: All donor plasma undergoes nucleic acid testing (NAT) for HIV, HBV, and HCV, exceeding many international standards to ensure the highest safety profile.
Scalable Manufacturing: Our partner facilities utilize advanced cold-ethanol fractionation and chromatography processes, ensuring high purity of IgG (typically >95%) and potent viral inactivation through specialized solvent/detergent (S/D) treatment and nanofiltration.
Cost-Efficiency: Through vertical integration of the supply chain, we offer Hepatitis B Human Immunoglobulin products at prices that enable wider accessibility for government healthcare tenders and private hospitals in developing regions.
Navigating the regulatory landscape for biologicals is complex. Jiangxi Serum Pharma provides comprehensive Localization & Compliance Support to ensure seamless market entry:
Provision of CTD/eCTD format dossiers, including Chemistry, Manufacturing, and Controls (CMC) data, for local MOH registrations.
HBIG requires strict 2°C to 8°C storage. We offer validated temperature-controlled packaging and real-time GPS/Temp monitoring during transit.
Assistance in obtaining GMP clearance, Certificate of Pharmaceutical Product (CPP), and Free Sale Certificates (FSC).
The industry is moving toward higher concentration formulations and subcutaneous delivery routes to improve patient compliance. Key trends we monitor include:
Customized stabilization for sensitive biological components.
Enhancing pharmaceutical solubility and physical properties.
Next-generation synthesis of nutritional and medical raw materials.
The vaccine triggers your body to produce its own antibodies (active immunity), taking weeks to work. HBIG provides pre-formed antibodies (passive immunity) for immediate protection, usually lasting 3–6 months.
Safety is ensured through rigorous donor screening, NAT testing for viruses, and multiple inactivation steps during manufacturing, such as S/D treatment and pasteurization.
No. HBIG is a biological product and must be kept in a cold chain (2-8°C). Exposure to high temperatures can denature the proteins and render the product ineffective.
We provide COA (Certificate of Analysis), GMP certificates, Stability Data, and full CTD dossiers to support local health authority approvals.
Exploring the shift toward sustainable sources in vaccine adjuvant production.
A look into the indispensable role of corticosteroids in modern emergency medicine.
Analyzing Eli Lilly's Foundayo™ (orforglipron) and its impact on the metabolic health market.
